2024 Cell And Gene Therapy Report: Advancing The Future Of Medicine

Despite near-universal optimism among oncologists about cell and gene therapies (CGTs), significant barriers could hinder their broader adoption. A recent survey of 124 U.S. oncologists found that while 99% agree CGTs are among the most important medical innovations of our time, many believe they are still "largely unproven". Key reasons oncologists cite for not prescribing CGTs to eligible patients include concerns about safety and side effects, as well as the patient's inability to manage direct and indirect costs.

Additionally, many patients referred for CGTs ultimately receive other treatments, with insurance coverage and out-of-pocket costs being the most common reasons. However, there is broad consensus on potential solutions, such as innovative payment models and expanding care into community settings.

To learn more about the challenges and opportunities for CGTs, access the full report.